Peroxisome Proliferator-activated Receptor Gamma Mutation in Familial Partial Lipodystrophy Type Three: A Case Report and Review of Literature

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2024 Dec 16

PMID 39676812

Authors

Chao-Jun Wu

Hao Liu

Li-Juan Tu

Jiong-Yu Hu

Affiliations

Soon will be listed here.

Abstract

Background: Familial partial lipodystrophy disease (FPLD) is a collection of rare genetic diseases featuring partial loss of adipose tissue. However, metabolic difficulties, such as severe insulin resistance, diabetes, hypertriglyceridemia, and hypertension frequently occur alongside adipose tissue loss, making it susceptible to misdiagnosis and delaying effective treatment. Numerous genes are implicated in the occurrence of FPLD, and genetic testing has been for conditions linked to single gene mutation related to FPLD. Reviewing recent reports, treatment of the disease is limited to preventing and improving complications in patients.

Case Summary: In 2017, a 31-year-old woman with diabetes, hypertension and hypertriglyceridemia was hospitalized. We identified a mutation in her peroxisome proliferator-activated receptor gamma () gene, Y151C (p.Tyr151Cys), which results in a nucleotide substitution residue 452 in the DNA-binding domain (DBD) of . The unaffected family member did not carry this mutation. Pioglitazone, a agonist, improved the patient's responsiveness to hypoglycemic and antihypertensive therapy. After one year of treatment in our hospital, the fasting blood glucose and glycosylated hemoglobin of the patient were close to normal.

Conclusion: We report a rare mutation, Y151C, which is located in the DBD of and leads to FPLD, and the preferred agent is agonists. We then summarized clinical phenotypic characteristics of FPLD3 caused by gene mutations, and clarified the relationship between different mutations of gene and the clinical manifestations of this type of FPLD. Additionally, current treatments for FPLD caused by mutations are reviewed.

References

Monajemi H, Zhang L, Li G, Jeninga E, Cao H, Maas M . Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 2007; 92(5):1606-12. DOI: 10.1210/jc.2006-1807. View

Hussain I, Garg A . Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016; 45(4):783-797. PMC: 7590232. DOI: 10.1016/j.ecl.2016.06.012. View

Miehle K, Porrmann J, Mitter D, Stumvoll M, Glaser C, Fasshauer M . Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3. Clin Endocrinol (Oxf). 2015; 84(1):141-8. DOI: 10.1111/cen.12837. View

Barroso I, Gurnell M, Crowley V, Agostini M, Schwabe J, Soos M . Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 2000; 402(6764):880-3. DOI: 10.1038/47254. View

Chen X, Ma Z, Chen P, Song X, Li W, Yu X . Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient. Front Endocrinol (Lausanne). 2022; 13:830708. PMC: 9001891. DOI: 10.3389/fendo.2022.830708. View

Garg A . Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350(12):1220-34. DOI: 10.1056/NEJMra025261. View

Jeru I, Vatier C, Vantyghem M, Lascols O, Vigouroux C . -associated partial lipodystrophy: anticipation of metabolic complications. J Med Genet. 2017; 54(6):413-416. DOI: 10.1136/jmedgenet-2016-104437. View

Lambadiari V, Kountouri A, Maratou E, Liatis S, Dimitriadis G, Karpe F . Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance. Front Endocrinol (Lausanne). 2021; 12:684182. PMC: 8217860. DOI: 10.3389/fendo.2021.684182. View

Savage D, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A . Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet. 2002; 31(4):379-84. DOI: 10.1038/ng926. View

10.

Castell A, Hieronimus S, Lascols O, Fournier T, Fenichel P . Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ. Diabetes Metab. 2012; 38(4):367-9. DOI: 10.1016/j.diabet.2012.02.012. View

11.

Savage D, Tan G, Acerini C, Jebb S, Agostini M, Gurnell M . Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 2003; 52(4):910-7. DOI: 10.2337/diabetes.52.4.910. View

12.

Singh S, Loke Y, Furberg C . Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007; 30(8):2148-53. DOI: 10.2337/dc07-0141. View

13.

Campeau P, Astapova O, Martins R, Bergeron J, Couture P, Hegele R . Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency. J Lipid Res. 2012; 53(9):1968-78. PMC: 3413236. DOI: 10.1194/jlr.P025437. View

14.

Rosen E, Spiegelman B . PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001; 276(41):37731-4. DOI: 10.1074/jbc.R100034200. View

15.

Alves M, Brites C, Sprinz E . HIV-associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag. 2014; 10:559-66. PMC: 4108257. DOI: 10.2147/TCRM.S35075. View

16.

Majithia A, Tsuda B, Agostini M, Gnanapradeepan K, Rice R, Peloso G . Prospective functional classification of all possible missense variants in PPARG. Nat Genet. 2016; 48(12):1570-1575. PMC: 5131844. DOI: 10.1038/ng.3700. View

17.

Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R . Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007; 33(5):385-9. DOI: 10.1016/j.diabet.2007.04.005. View

18.

Scott L, Mohlke K, Bonnycastle L, Willer C, Li Y, Duren W . A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007; 316(5829):1341-5. PMC: 3214617. DOI: 10.1126/science.1142382. View

19.

Visser M, Kropman E, Kranendonk M, Koppen A, Hamers N, Stroes E . Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C). Diabetologia. 2011; 54(7):1639-44. PMC: 3110271. DOI: 10.1007/s00125-011-2142-4. View

20.

Tontonoz P, Hu E, Spiegelman B . Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev. 1995; 5(5):571-6. DOI: 10.1016/0959-437x(95)80025-5. View